News >

Ongoing Research Builds Upon Advances in Stage III NSCLC, ALK+ Disease

Brandon Scalea
Published: Saturday, Apr 27, 2019

Ronan J. Kelly, MD, MBA

Ronan J. Kelly, MD, MBA

Although the PACIFIC trial introduced a new standard of care in the treatment of patients with inoperable stage III non–small cell lung cancer (NSCLC) by administering durvalumab (Imfinzi) post chemoradiotherapy, investigators are now trying to determine whether the combination of durvalumab plus chemoradiotherapy concurrently is safe and effective, said Ronan J. Kelly, MD, MBA.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication